Abstract: Poster Presentations |

Metastatic Non-lung Cancer Carcinomas and Sarcomas Treated with Photodynamic Therapy –A Phase II Study FREE TO VIEW

Evelio Rodriguez, MD; Joseph S. Friedberg, MD; Shamus R. Carr, MD; Joshua P. Cantor, MD*; Dianna Stripp; James P. Stevenson, MD; Timothy Zhu, PhD; Debbie Smith, RN; Melissa Culligan, RN; Andrea Dimofte, PhD; Eli Glatstein, MD; Stephen M. Hahn, MD
Author and Funding Information

Thomas Jefferson University, Philadelphia, PA


Chest. 2004;126(4_MeetingAbstracts):804S. doi:10.1378/chest.126.4_MeetingAbstracts.804S
Text Size: A A A
Published online


PURPOSE:  Malignant pleural metastasis occurs in 15-20% of patients with metastatic disease. The median survival for these patients is 4 months, with a 1-year survival of less than 15%. In an attempt to decrease local recurrence and increase overall survival, surgical debulking and intraoperative hemithoracic photodynamic therapy (PDT) was performed on patients with metastatic pleural malignancies. The objectives were to examine local control and effect on survival.

METHODS:  10 patients (17-74 years old) with metastatic cancer (2 ovarian, 5 sarcoma, 1 thymoma, 1 pheochromocytoma, 1 breast) isolated to one pleural space were enrolled (9/10 bulk disease, 1 effusion alone). 9/10 were proven unresponsive to conventional therapy. Patients received porfirmer sodium (2mg/kg) 24 hours prior to surgery, underwent resection of all gross tumor and received intraoperative hemithoracic illumination with 30 J/cm2 630 nm light (9 thoracotomies, 1 thoracoscopy). Local recurrence was assessed with CT scans every three months.

RESULTS:  Due to intraoperative death, 2/5 patients with sarcoma did not receive PDT. One patient with sarcoma is alive at 2.0 months. The remaining 2/5 patients with sarcoma survived 1.9 and 6.5 months, both dying with local recurrences. The patient with pheochromocytoma is alive at 21.0 months postoperatively, but diagnosed with local recurrence at 20.0 months. The patient with thymoma is alive without recurrence at 20.4 months. The patient with metastatic breast cancer is alive at 14.7 months, but with recent brain metastases. One patient with ovarian cancer died after 7.7 months with locally recurrent disease and the other, treated thoracoscopically, was alive with abdominal recurrence at 25.5 months (then lost to follow-up). There were no significant PDT related complications.

CONCLUSION:  In select situations, combining surgery and PDT for patients with secondary cancers involving the pleura may be effective in controlling local recurrence and increasing overall survival. Patients with sarcomas appear to be the most difficult to treat and the least likely to derive significant benefit.

CLINICAL IMPLICATIONS:  PDT may be an effective adjuvant therapy to decrease local recurrence of pleural metastases.

DISCLOSURE:  J.P. Cantor, Photofrin

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543